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Systemic Lupus Erythematosus (SLE) is an autoimmune 
disease with heterogeneous clinical manifestations 
including fatigue. Previous studies aimed at proving the 
relationship between fatigue and SLE disease activity 
showed conflicting results. In 2015, Asia Pacific Lupus 
Collaboration (APLC) developed low disease activity 
criteria, named Lupus Low Disease Activity State 
(LLDAS). Patients who spend more time in LLDAS have 
significantly lower morbidity. This study aimed to 
evaluate the association between disease activity based 
on LLDAS and fatigue.  
Methods: This is a analytical cross-sectional study. 
Subjects were SLE patients at rheumatology clinic in 
Dr. Hasan Sadikin Hospital, Bandung during June-
January 2018. Subjects were evaluated based on 
LLDAS criteria and divided into 2 groups: LLDAS 
and non-LLDAS. Fatigue status of the subjects was 
assessed with Fatigue Severity Scale (FSS).  
Results: A hundred and thirty-three subjects were 
included in this study, divided into 63 subjects in 
LLDAS group and 60 subjects in non-LLDAS group. 
Nineteen subjects (30.2%) in LLDAS group had 
fatigue and 39 subjects (65%) in non-LLDAS had 
fatigue. There was a significant association between 
LLDAS and fatigue (p< 0.001). Nonetheless, fatigue 
level in LLDAS group was still high since disease 
activity was not the only factor related to fatigue. 
Fatigue may be a distinct clinical manifestation of 
neuropsychiatric lupus and may be independent of 
lupus disease activity Conclusions: There was a 
significant association between LLDAS and fatigue 
showed by lower fatigue level was found in the 
LLDAS group than in the non-LLDAS group.  
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Systemic Lupus Erythematosus (SLE) is a chronic 
autoimmune disease characterized by various 
clinical manifestations.1-4 Clinical manifestations 
are vary among individuals, from minimally 
symptomatic to life-threatening condition.4-7 
Fatigue is one of most important manifestations of 
SLE and also affects physical, social, and 
emotional functioning. Most individuals with SLE 
reported fatigue to be most disabling symptom.8 
 
 
Fatigue could be mediated from any physical 
illness but also from social distress or depression. 
Fatigue can be measured subjectively by using a 
self-administered questionnaire. Fatigue Severity 
Scale (FSS) is a questionnaire, consists of 9 
questions to determine fatigue severity 
subjectively. It is proven to have high validity and 
consistency, also in identifying fatigue in chronic 
disease adequately.9-11  
Objective clinical parameters are needed to 
monitor fluctuation of SLE disease activity. In 
2015, Asia Pacific panel of SLE experts developed 
low disease activity criteria, named Lupus Low 
Disease Activity State (LLDAS). LLDAS is 
defined as a low disease activity state, which, if 
persists, is associated with a lower likelihood of 
poor outcome, considering disease activity and 
drug safety. Patients spends more time in LLDAS 
have significantly reduced morbidity due to organ 
damage.12  
Previous studies aimed at proving the 
relationship between fatigue and SLE disease 
activity showed conflicting results. This study uses 
LLDAS criteria in determining SLE disease 
activity. The aim was to evaluate the association 





This is a analytical cross-sectional study. Subjects 
were SLE patients at Rheumatology Clinic Dr. 
Hasan Sadikin Hospital, Bandung in June –August 
2017. This study has involved subjects of Asia 
Pacific Lupus Collaboration LLDAS Validation 
Study.  
Inclusion criteria of this study were SLE 
patients who were 18 years old or older, were 
evaluated according to the American College of 
Rheumatology (ACR) 1997 13 or Systemic Lupus 
International Collaborating Clinics (SLICC) 
2012,14 also those who could read, write and 
understand the given informed consent. Exclusion 
criteria of this study were pregnant women, patient 
with poor medical state, or with psychiatric 
disturbance and uncooperative. Subjects were 
evaluated based on LLDAS criteria and divided 
into 2 groups: LLDAS and non-LLDAS. Fatigue 
status of the subjects were assessed individually 
using FSS. 
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Ethics 
The study was approved by The Health Research Ethics 
Committee, Dr. Hasan Sadikin Hospital Bandung. 
 
Statistics 
All collected data was analyzed using the SPSS v20.0. 
Categorical data was presented in frequency and percentage. 
Categorical analysis between fatigue and disease activity 
based on LLDAS were analyzed using Chi-squared test, while 
numerical analysis between FSS score and LLDAS were 
analyzed using independent T-test, considered as statistically 




Table 1. Basic Characteristics  
 Non-LLDAS LLDAS  
Variable (n=60) (n=63) p value 
Age (Years), 32 (20-57) 35 (19-62) 0.047 a 
(median (min-max))      
Sex, n (%)      
Male 2 (3.3) 3 (4.8) 0.523 b 
Female 58 (96.7) 60 (95.2)  
Educational background,     
n (%)      
Elementary school 6 (10.0) 7 (11.1) 0.544 b 
Junior high school 11 (18.3) 6 (9.5)  
Senior high school 29 (48.3) 38 (60.3)  
Diploma III 6 (10.0) 4 (6.3)  
Bachelor 8 (13.3) 8 (12.7)  
Occupation, n (%)      
Housewife 37 (62.7) 36 (57.1) 0.317 b 
College student 3 (5.1) 5 (7.9)  
Private employee 13 (22.0) 10 (15.9)  
Civil servant 0 (0.0) 5 (7.9)  
Entrepreneur 2 (3.4) 2 (3.2)  
Not employed 4 (6.8) 5 (7.9)  
Duration of Illness from 4 (1-19) 6 (1-30) 0,009 a* 
Diagnosis (years), (median     
(min-max))      
Note: Data analysis use a Independent T-test, b Fischer Exact  
*significant if p < 0,05      
 
Table 2. Fatigue measurement using Fatigue Severity 
Scale (FSS) based on LLDAS criteria 
 FSS a 
Fatigue, 












    
Non-LLDAS (n=32) 39.27 ± 10.3 39 (65.0) 21 (35.0) <0.001 b 
LLDAS (n=30) 30.25 ± 11.0 19 (30.2) 44 (69.8)  
 
Note: SD = Standard Deviation, n = frequency, a T 
test for FSS mean score in Non-LLDAS vs LLDAS 
group significant (p= <0.001); b Chi-square test 
 
Data collection was conducted during June –January 2018, at 
Rheumatology Clinic Dr. Hasan Sadikin Hospital, Bandung. A 
hundred and twenty-three patients who met the inclusion 
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criteria were included in the study, divided into 63 subjects in 
LLDAS group and 60 subjects in non-LLDAS group.  
Out of 123 patients, 118 (95.9%) were female. Patients 
from LLDAS group aged between 19-62 years old (median 35 
years old) and non-LLDAS group aged 20-57 years old 
(median 32 years old). Both groups were matched for 
education and occupational status. Median duration of illness 
in LLDAS patients was longer than median duration of illness 
in non-LLDAS patients (median 6 years [1-30 years] vs 4 
years ([1-19 years]). Baseline characteristics of study subjects 
were shown in Table 1.  
Less than half subjects (30.2%) from LLDAS group had 
higher incidence of fatigue with mean FSS score 30.25 (SD 
11.0), ranged from 9-59. Thirty-nine subjects (65.0%) from 
non-LLDAS group had significantly higher incidence of 
fatigue with mean FSS score 39.27 (SD 10.3), ranged from 18-
62 (P value< 0.001). The non-LLDAS group had higher 
incidence of fatigue than LLDAS group. Chi-square analysis 
revealed significant association (p<0.001) between SLE 




This study revealed significant association between SLE 
disease activity based on LLDAS criteria and fatigue. Subjects 
from LLDAS group had lower incidence of fatigue than non-
LLDAS group, nevertheless fatigue also an issue to patients in 
LLDAS group.  
This finding aligned with study by Tench et.al. , in which 
patients with higher disease activity showed significant 
incidence of fatigue rather than those who had lower disease 
activity, but fatigue was still burdensome to patients with low 
SLE activity. In the study, Systemic Lupus Activity Measure 
(SLAM) and European Consensus Lupus Activity Measure 
(ECLAM) were utilized to measure disease activity, which 
fatigue was one determining components. 15  
Fatigue is considered one of most important symptom and 
also contributes to physical, social and emotional 
malfunctioning. Study by Krupp et al. showed more than half 
SLE patients reported fatigue as most irritating symptom out 
of all SLE disease activity.16 Fatigue is an outcome from 
sickness behavior mechanism due to SLE disease activity. 
Proinflammatory cytokines, such as IL-1β, IL-6, TNF-α play 
major role in pathophysiology of fatigue in SLE. In high SLE 
disease activity, more cytokines were produced; therefore 
there were higher incidence of fatigue. In the brain, those 
cytokines inducing a behavioral response called sickness 
behavior, characterized by fatigue, decreased physical 
activity, drowsiness, which were defense mechanism in 
avoiding any further damage. In high SLE disease activity, 
more cytokines were produced, therefore there were higher 
incidence of fatigue.17  
Contradicted with study by Tench et al.15, Wang et al.18 
suggested that there was no significant correlation between 
SLE disease activity and fatigue. In these studies, disease 
activity was measured by Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI) criteria, which did not 
include fatigue in the scoring. Study showed that fatigue was 
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correlated with depression, which usually co-expressed in 
SLE patients.  
Similarly, study by McKinley et al. reported there was no 
direct correlation between SLE disease activity and fatigue 
itself. This study use Systemic Lupus Activity Measure minus 
Fatigue (SLAM-F) criteria to evaluate SLE disease activity. 
SLAM-F criteria has no longer contains “fatigue” as scoring 
component as well as SLEDAI criteria. The study signified 
that SLE disease activity has no direct correlation with fatigue, 
but through another mediator variable such as sleep disruption 
and depression. 19  
Unlike previous studies by Tench et al.15, Wang et al.18 and 
McKinley et al.19, subjects in this study were divided into two 
groups based on subject’s disease activity of LLDAS criteria. 
There are five criteria that must be fulfilled when using LLDAS 
criteria in evaluating SLE disease activity, in which SLEDAI-2K 
score ≤ 4, SELENA-SLEDAI physician global assessment 
(PGA) ≤ 1, no new lupus disease activity compared to the 
previous assessment, and also well tolerated and low dose 
medication. Patients spends more time in LLDAS have 
significantly reduced morbidity due to organ damage.12  
This study revealed despite significant correlation between 
SLE disease activity based on LLDAS criteria and fatigue, 
fatigue consistently became an issue to subjects from LLDAS 
group. Fatigue can manifest from the disease activity itself but 
also from other factors. Other factors which contributed to 
fatigue in SLE were mood disorders, disease control 
mechanisms, physical activities, depresssion, poor sleep 
quality, and psychosocial factors such as emotional distress, 
anxiety, quality of life and personality traits.20,21  
More than half subjects from both LLDAS and non-
LLDAS group were housewives. Burgos et al 22 reported 
occupation affects subject’s physical activity, thus physical 
activity was another factor that influence incidence of fatigue 
other than disease activity. Omdal et al.20 reported among 57 
subjects with low SLE disease activity based on SLEDAI 
criteria, there were no correlation between SLE disease 
activity and fatigue, however the strongest and most 
consistent factor was psychosocial factor. This corresponds 
well with other studies by Wang et al.18 and McKinley et al.19, 
which suggested no correlation between disease activity based 
on SLEDAI criteria and fatigue, nonetheless psychosocial 
factor was the one most contributing factor. There were high 
possibilities that fatigue was caused by other psychosocial 
factor that indicated high incidence of fatigue in LLDAS 
group. This study only measured fatigue using SLE disease 
activity based on LLDAS, but did not evaluated subject’s 
psychosocial factors from both groups.  
There are some limitations in this study. Duration of illness 
in LLDAS group was longer than non-LLDAS group, which 
could affect subject’s disease coping mechanism, furthermore the 
incidence of fatigue. This study only measured fatigue using SLE 
disease activity based on LLDAS, but did not evaluated subject’s 
psychosocial or other contributing factors from both groups. 
These subjects were not tested for depression with any depression 
diagnostic criteria such as Beck Depression Inventory or Patient 




how strong the correlation between SLE disease activity based 
on LLDAS and fatigue was not feasible. 
 
CONCLUSSION 
This study showed significant association between LLDAS 
and fatigue. Lower fatigue level was found in LLDAS group 
in comparison to the non-LLDAS group. Fatigue may be a 
distinct clinical manifestation of neuropsychiatric lupus and 
may be independent of lupus disease activity. 
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